LEO Pharma strengthens global leadership team with appointment of new Executive Vice President, Global Therapeutic & Value Strategy
Ballerup, September 23, 2020 – LEO Pharma A/S today announced that Becki Morison will join the Global Leadership Team as Executive Vice President, Global Therapeutic & Value Strategy, effective October 1.
Morison joins LEO Pharma from Eli Lilly, where she was VP, US Immunology. Prior to that, she held several leadership positions in the US, Australia as well as in the United Kingdom and the Nordics. In addition to her international experience, Morison has a proven track record in building and growing innovative pharmaceutical
franchises in different therapeutic areas including orphan diseases.
“Becki Morison’s broad knowledge in immunology, dermatology and specialty pharma will help us to strategically develop our innovative portfolio and execute global launches of best or first-in-class medicines, which is essential to reach our ambition of becoming a global leader in medical dermatology,” said Catherine Mazzacco, President and CEO of LEO Pharma.
Morison succeeds Patrice Baudry, who will take over responsibility for establishing LEO Pharma’s rare disease presence.
“Patrice Baudry’s medical background and his experience in building strong value propositions for our medicines, as he did successfully for our thrombosis business, will be vital in establishing LEO Pharma in rare dermatologic diseases,” Mazzacco continued.
+45 3140 6180
About LEO Pharma
The company is a leader in medical dermatology with a robust R&D pipeline, a wide range of therapies and a pioneering spirit. Founded in 1908 and owned by the LEO Foundation, LEO Pharma has devoted decades of research and development to advance the science of dermatology, setting new standards of care for people with skin conditions. LEO Pharma is headquartered in Denmark with a global team of 6,000 people, serving 92 million patients in 130 countries.
Subscribe to releases from LEO Pharma
Subscribe to all the latest releases from LEO Pharma by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from LEO Pharma
LEO Pharma sells portfolio of four products to Cheplapharm31.8.2020 12:34:26 CEST | Press release
- Sale of four products for EUR 300 million - Important milestone in LEO Pharma’s ambitious 2030 strategy with increased focus on new innovative solutions for medical dermatology - Transaction expected to close December 2020
LEO Pharma strengthens global leadership team with appointment of new EVP People & Communications18.8.2020 12:02:29 CEST | Press release
Ballerup, August 18, 2020 – LEO Pharma A/S today announced that Dennis Schmidt Pedersen will join the executive leadership team as Executive Vice President Global People & Communications, effective September 1, 2020.
LEO Pharma announces U.S. Food and Drug Administration Fast Track designation for delgocitinib cream for the treatment of adults with moderate-to-severe chronic hand eczema4.8.2020 14:05:39 CEST | Press release
The purpose of the Fast Track process is to get important potential new drugs to patients earlier (1)
LEO Pharma announces U.S. Food and Drug Administration (FDA) acceptance of Biologics License Application (BLA) for tralokinumab for the treatment of adults with moderate-to-severe atopic dermatitis9.7.2020 14:00:00 CEST | Press release
Submission includes data from pivotal ECZTRA 1, 2 and ECZTRA 3 Phase 3 studies evaluating safety and efficacy of tralokinumab.
LEO Pharma strengthens global leadership team30.6.2020 12:43:59 CEST | Press release
Ballerup, June 30, 2020 – LEO Pharma, a global leader in medical dermatology, today announced that Dr. Monica Shaw, M.D., and Nathalie Joannes will join the executive leadership team adding seasoned experience and international profile to LEO Pharma.
LEO Pharma presents results from study of twice-weekly Enstilar® (calcipotriene and betamethasone dipropionate) Foam for topical use in long-term maintenance treatment of plaque psoriasis12.6.2020 21:20:42 CEST | Press release
New results from the PSO-LONG clinical trial are the first to provide long-term maintenance data for plaque psoriasis with a twice-weekly topical treatment with Enstilar®(calcipotriene and betamethasone dipropionate) Foam Plaque psoriasis is a chronic, multifactorial disease affecting nearly 80% of the 125 million people living with psoriasis worldwide(1,2) LEO Pharma is committed to building on its more than 30-year heritage of pursuing innovative products for patients affected by psoriasis and other chronic skin conditions BALLERUP, Denmark, JUNE 12, 2020 – LEO Pharma A/S, a global leader in medical dermatology, today presented results from the Phase 3 PSO-LONG clinical trial. PSO-LONG compared the efficacy and safety of twice-weekly Enstilar® (calcipotriene and betamethasone dipropionate)Foam, versus foam vehicle for long-term (52-week) maintenance treatment for adult patients with plaque psoriasis.(3,4) Results were presented as ePosters online at the American Academy of Dermatolog
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom